Assignee
EDITAS MEDICINE INC
US·49 granted patents·73 pending applications·255 citations·filing 2014–2025
Top patents by PatentIndex Score
122 records- 0198US10190137B2CRISPR-related methods and compositions with governing gRNASEDITAS MEDICINE INC·Filed 2017·Granted Jan 29, 2019·37 cites·26 claims
- 0298US9834791B2CRISPR-related methods and compositions with governing gRNASEDITAS MEDICINE INC·Filed 2014·Granted Dec 5, 2017·97 cites·30 claims
- 0397US11390887B2CRISPR-related methods and compositions with governing gRNASEDITAS MEDICINE INC·Filed 2020·Granted Jul 19, 2022·6 cites·8 claims
- 0497US10640788B2CRISPR-related methods and compositions with governing gRNAsEDITAS MEDICINE INC·Filed 2019·Granted May 5, 2020·18 cites·25 claims
- 0595US10253312B2CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10)EDITAS MEDICINE INC·Filed 2018·Granted Apr 9, 2019·13 cites·29 claims
- 0695US9963719B1Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNAEDITAS MEDICINE INC·Filed 2017·Granted May 8, 2018·15 cites·14 claims
- 0794US9938521B2CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)EDITAS MEDICINE INC·Filed 2015·Granted Apr 10, 2018·12 cites·39 claims
- 0893US12234449B2CRISPR/Cas-related methods and compositions for treating Leber's congenital amaurosis 10 (LCA10)EDITAS MEDICINE INC·Filed 2022·Granted Feb 25, 2025·1 cites·17 claims
- 0992US11028388B2CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosaEDITAS MEDICINE INC·Filed 2015·Granted Jun 8, 2021·7 cites·22 claims
- 1092US10006054B1Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNAEDITAS MEDICINE INC·Filed 2018·Granted Jun 26, 2018·6 cites·18 claims
- 1191US10428319B2Engineered Cas9 nucleasesEDITAS MEDICINE INC·Filed 2018·Granted Oct 1, 2019·9 cites·20 claims
- 1290US12201699B2Compositions and methods for promoting homology directed repairEDITAS MEDICINE INC·Filed 2021·Granted Jan 21, 2025·1 cites·17 claims
- 1390US11268086B2CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10)EDITAS MEDICINE INC·Filed 2019·Granted Mar 8, 2022·3 cites·41 claims
- 1490US11236313B2Cas9 fusion molecules, gene editing systems, and methods of use thereofEDITAS MEDICINE INC·Filed 2017·Granted Feb 1, 2022·4 cites·14 claims
- 1589US11390884B2Optimized CRISPR/cas9 systems and methods for gene editing in stem cellsEDITAS MEDICINE INC·Filed 2016·Granted Jul 19, 2022·7 cites·16 claims
- 1686US12264331B2Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNAEDITAS MEDICINE INC·Filed 2023·Granted Apr 1, 2025·0 cites·26 claims
- 1785US11339437B2Compositions and methods for treating CEP290-associated diseaseEDITAS MEDICINE INC·Filed 2017·Granted May 24, 2022·3 cites·117 claims
- 1884US11566263B2Compositions and methods for treating CEP290 associated diseaseEDITAS MEDICINE INC·Filed 2017·Granted Jan 31, 2023·3 cites·28 claims
- 1984US11098297B2Engineered Cas9 nucleasesEDITAS MEDICINE INC·Filed 2019·Granted Aug 24, 2021·2 cites·13 claims
- 2084US11028411B2Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNAEDITAS MEDICINE INC·Filed 2019·Granted Jun 8, 2021·1 cites·28 claims
- 2184US2025288698A1Compositions and methods for promoting homology directed repairEDITAS MEDICINE INC·Filed 2024·Application pending·0 cites
- 2283US12359223B2Systems and methods for modulating chromosomal rearrangementsEDITAS MEDICINE INC·Filed 2019·Granted Jul 15, 2025·2 cites·18 claims
- 2383US11001844B2CRISPR/Cas-related methods and compositions for treating herpes simplex virusEDITAS MEDICINE INC·Filed 2018·Granted May 11, 2021·2 cites·26 claims
- 2482US11242525B2CRISPR/CAS-related methods and compositions for treating sickle cell diseaseEDITAS MEDICINE INC·Filed 2015·Granted Feb 8, 2022·2 cites·28 claims
- 2580US2022389460A1CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNASEDITAS MEDICINE INC·Filed 2022·Application pending·0 cites
- 2680US2024067992A1Human hematopoietic stem cell having a modified bcl11a gene and methods of making the cellEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 2778US11692205B2Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNAEDITAS MEDICINE INC·Filed 2021·Granted Jul 4, 2023·0 cites·6 claims
- 2878US11141493B2Compositions and methods for treating CEP290-associated diseaseEDITAS MEDICINE INC·Filed 2018·Granted Oct 12, 2021·2 cites·35 claims
- 2976US2026034247A1Compositions and methods for treating cep290-associated diseaseEDITAS MEDICINE INC·Filed 2024·Application pending·0 cites
- 3075US11680268B2Methods for improving CRISPR/Cas-mediated genome-editingEDITAS MEDICINE INC·Filed 2015·Granted Jun 20, 2023·1 cites·17 claims
- 3175US2024294917A1Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)EDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 3274US2023365980A1Methods for improving crispr/cas-mediated genome-editingEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 3373US12049651B2Cas9 fusion molecules, gene editing systems, and methods of use thereofEDITAS MEDICINE INC·Filed 2021·Granted Jul 30, 2024·0 cites·18 claims
- 3473US2024084348A1Nucleic acid mutagenesis methodsEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 3572US12545912B2CRISPR/Cas-related methods and compositions for treating usher syndrome and retinitis pigmentosaEDITAS MEDICINE INC·Filed 2021·Granted Feb 10, 2026·0 cites·20 claims
- 3672US12297466B2Engineered Cas9 nucleasesEDITAS MEDICINE INC·Filed 2021·Granted May 13, 2025·0 cites·6 claims
- 3772US2024117383A1Selection by essential-gene knock-inEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 3872US2024132877A1Genome editing systems comprising repair-modulating enzyme molecules and methods of their useEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 3972US2024167059A1Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sitesEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 4071US2023313174A1Emulsion-based screening methodsEDITAS MEDICINE INC·Filed 2022·Application pending·0 cites
- 4171US2023340456A1Use of exonucleases to improve crispr/cas-mediated genome editingEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 4270US10494649B2Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNAEDITAS MEDICINE INC·Filed 2018·Granted Dec 3, 2019·0 cites·6 claims
- 4370US2026035693A1Systems and methods for the treatment of hemoglobinopathiesEDITAS MEDICINE INC·Filed 2024·Application pending·0 cites
- 4470US2024141386A1Compositions and methods for treating cep290 associated diseaseEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 4570US2024360471A1Crispr/cas-related methods and compositions for treating beta hemoglobinopathiesEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 4670US2025179488A1Systems and methods for the treatment of hemoglobinopathiesEDITAS MEDICINE INC·Filed 2024·Application pending·0 cites
- 4769US11834649B2CRISPR/CAS-related methods and compositions for treating herpes simplex virusEDITAS MEDICINE INC·Filed 2021·Granted Dec 5, 2023·0 cites·21 claims
- 4868US2022273818A1Compositions and methods for treating cep290-associated diseaseEDITAS MEDICINE INC·Filed 2021·Application pending·0 cites
- 4968US2025297288A1Genome editing of b cellsEDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 5068US2023026726A1Crispr/cas-related methods and compositions for treating sickle cell diseaseEDITAS MEDICINE INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 122 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when EDITAS MEDICINE INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →